インフルエンザ検査の世界市場予測（～2021年）：迅速インフルエンザ検出、ウイルス培養、直接免疫蛍光分析（DFA）、血清学的検査、分子診断...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.2.1 MARKETS COVERED 15
1.2.2 YEARS CONSIDERED IN THE REPORT 15
1.3 CURRENCY 16
1.4 LIMITATIONS 16
1.5 STAKEHOLDERS 16

2 RESEARCH METHODOLOGY 17
2.1 MARKET SIZE ESTIMATION 18
2.2 MARKET RANKING ANALYSIS 20
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 21
2.3.1 KEY DATA FROM SECONDARY SOURCES 22
2.3.2 KEY DATA FROM PRIMARY SOURCES 23
2.3.3 ASSUMPTIONS FOR THE STUDY 23

3 EXECUTIVE SUMMARY 24
3.1 INTRODUCTION 24
3.2 CONCLUSION 28

4 PREMIUM INSIGHTS 29
4.1 INFLUENZA DIAGNOSTICS: MARKET OVERVIEW 29
4.2 GEOGRAPHIC ANALYSIS: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE (2016) 30
4.3 MOLECULAR DIAGNOSTIC TESTS MARKET SIZE, BY TYPE, 2016 VS. 2021 (USD MILLION) 31
4.4 LIFE CYCLE ANALYSIS, BY REGION (2016) 31

5 MARKET OVERVIEW 32
5.1 INTRODUCTION 33
5.2 DRIVERS 34
5.2.1 INCREASING PREVALENCE OF INFLUENZA 34
5.2.2 GROWTH IN RESEARCH FUNDING FOR INFLUENZA DIAGNOSTICS 34
5.2.3 RISING DEMAND FOR FASTER DIAGNOSIS AND CONTROL OF INFLUENZA 34
5.3 RESTRAINTS 35
5.3.1 VARIABILITY IN SENSITIVITY AND SPECIFICITY AMONG INFLUENZA DIAGNOSTIC TESTS 35
5.3.2 STRINGENT REGULATORY FRAMEWORK 35
5.3.3 RISING HEALTHCARE COSTS LIMITING THE USAGE OF NOVEL INFLUENZA DIAGNOSTIC TECHNIQUES 35
5.4 OPPORTUNITIES 35
5.4.1 ADVANCEMENTS IN GENOMIC AND PROTEOMIC TECHNOLOGIES 35
5.4.2 SIGNIFICANT GROWTH PROSPECTS IN DEVELOPING COUNTRIES 36
5.5 CHALLENGE 36
5.5.1 DEARTH OF SKILLED PERSONNEL TO HANDLE ADVANCED INFLUENZA DIAGNOSTIC TOOLS 36
5.6 REGULATORY FRAMEWORK 36
5.6.1 NORTH AMERICA 36
5.6.2 EUROPE 37
5.6.3 ASIA-PACIFIC 37
5.6.3.1 India 37
5.6.3.2 China 37
5.6.3.3 Australia 38

6 INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE 39
6.1 INTRODUCTION 40
6.2 TRADITIONAL DIAGNOSTIC TESTS 41
6.2.1 RAPID INFLUENZA DETECTION TESTS (RIDT) 43
6.2.2 VIRAL CULTURE 44
6.2.3 DIRECT FLUORESCENT ANTIBODY (DFA) TESTS 46
6.2.4 SEROLOGICAL ASSAYS 48
6.3 MOLECULAR DIAGNOSTIC TESTS 50
6.3.1 RT-PCR 52
6.3.2 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION (NASBA) TESTS 53
6.3.3 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAYS (LAMP) 55
6.3.4 SIMPLE AMPLIFICATION-BASED ASSAYS (SAMBA) 56
6.3.5 OTHER MOLECULAR DIAGNOSTIC TESTS 57

7 INFLUENZA DIAGNOSTICS MARKET, BY END USER 60
7.1 INTRODUCTION 61
7.2 HOSPITALS/CLINICAL LABORATORIES 61
7.3 REFERENCE LABORATORIES 63
7.4 OTHER END USERS 64

8 INFLUENZA DIAGNOSTICS MARKET, BY REGION 66
8.1 INTRODUCTION 67
8.2 PEST ANALYSIS 68
8.2.1 POLITICAL FACTORS 68
8.2.2 ECONOMIC FACTORS 68
8.2.3 SOCIOCULTURAL FACTORS 68
8.2.4 TECHNOLOGICAL FACTORS 69
8.3 EUROPE 70
8.3.1 GERMANY 73
8.3.2 U.K. 75
8.3.3 REST OF EUROPE 77
8.4 NORTH AMERICA 79
8.4.1 U.S. 82
8.4.2 CANADA 84
8.5 ASIA-PACIFIC 87
8.6 REST OF THE WORLD (ROW) 89

9 COMPETITIVE LANDSCAPE 92
9.1 OVERVIEW 92
9.2 LEADING PLAYERS IN THE INFLUENZA DIAGNOSTICS MARKET 93
9.3 COMPETITIVE SITUATION AND TRENDS 94
9.3.1 PRODUCT LAUNCHES AND APPROVALS 94
9.3.2 ACQUISITIONS 95
9.3.3 EXPANSIONS 96
9.3.4 COLLABORATIONS AND AGREEMENTS 97

10 COMPANY PROFILES 98
10.1 INTRODUCTION 98
(Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, Ratio Analysis, MnM View)*
10.2 F. HOFFMANN-LA ROCHE AG 99
10.3 BECTON, DICKINSON AND COMPANY 101
10.4 THERMO FISHER SCIENTIFIC INC. 103
10.5 ALERE INC. 105
10.6 DIASORIN S.P.A. 107
10.7 QUIDEL CORPORATION 109
10.8 MERIDIAN BIOSCIENCE, INC. 111
10.9 ANALYTIK JENA AG (A SUBSIDIARY OF ENDRESS+HAUSER AG) 112
10.10 LUMINEX CORPORATION 114
10.11 SA SCIENTIFIC, LTD. 116
*Details on Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
 

11 APPENDIX 117
11.1 INSIGHTS OF INDUSTRY EXPERTS 117
11.2 DISCUSSION GUIDE 118
11.3 OTHER DEVELOPMENTS 120
11.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 121
11.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 123
11.6 AVAILABLE CUSTOMIZATIONS 125
11.7 RELATED REPORTS 126
11.8 AUTHOR DETAILS 127